Back to top
more

Coherus Oncology, Inc. (CHRS)

(Delayed Data from NSDQ)

$1.61 USD

1.61
2,798,149

+0.08 (5.23%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $1.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (101 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Coherus BioSciences (CHRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Coherus BioSciences (CHRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why Coherus BioSciences (CHRS) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Coherus BioSciences (CHRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Coherus BioSciences (CHRS) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

CHRS or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CHRS vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Coherus BioSciences (CHRS) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 169.23% and 35.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Coherus BioSciences (CHRS) Q2 Earnings Expected to Decline

by Zacks Equity Research

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Coherus BioSciences (CHRS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Anirudha Bhagat headshot

Check These 7 Top-Ranked Stocks With Solid Net Profit Margins

by Anirudha Bhagat

Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.

Zacks Equity Research

The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products

by Zacks Equity Research

The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products

Tirthankar Chakraborty headshot

Signs of Coronavirus Slowdown Pep Up Wall Street: 5 Winners

by Tirthankar Chakraborty

Wall Street continues to build on a steep rebound in the previous session after lockdown strategy stabilized coronavirus outbreak in the United States and abroad.

Zacks Equity Research

Is Coherus BioSciences (CHRS) Stock a Solid Choice Right Now?

by Zacks Equity Research

Coherus BioSciences (CHRS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities

by Zacks Equity Research

Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities

Zacks Equity Research

Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance

by Zacks Equity Research

FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.

Zacks Equity Research

5 Stocks Trading Near 52-Week High That Can Scale Higher

by Zacks Equity Research

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Zacks Equity Research

Coherus (CHRS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

We expect Coherus BioSciences (CHRS) to provide updates on its pipeline when it releases fourth-quarter 2019 results.

Zacks Equity Research

Coherus BioSciences (CHRS) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Coherus BioSciences (CHRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Has Coherus BioSciences (CHRS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (CHRS) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status

by Zacks Equity Research

The FDA grants fast track status to Arena's (ARNA) early-stage candidate, APD418, for the treatment of decompensated heart failure.

Zacks Equity Research

Amarin Posts '19 Preliminary Results, Gives 2020 Expense View

by Zacks Equity Research

Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020. However, the operating expense guidance for 2020 was higher than expected, which probably pulled the stock down.

Zacks Equity Research

Is Coherus BioSciences (CHRS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (CHRS) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Protagonist (PTGX) Starts Study on PTG-300 for Blood Disorder

by Zacks Equity Research

Protagonist's (PTGX) phase II study on PTG-300 will evaluate it as a potential treatment for hereditary hemochromatosis, a rare blood disorder, caused due to accumulation of iron.

Zacks Equity Research

Pulmatrix Surges on License Agreement With Johnson & Johnson

by Zacks Equity Research

Pulmatrix (PULM) inks an agreement with an entity of J&J, granting it the license to develop a portfolio of narrow spectrum kinase inhibitors for lung cancer interception.

Zacks Equity Research

Arena (ARNA) Expands Strategic Deal With Beacon Discovery

by Zacks Equity Research

Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.

Zacks Equity Research

Flexion's (FLXN) Stock Up on FDA Approval for Zilretta sNDA

by Zacks Equity Research

Flexion's (FLXN) sNDA for osteoarthritis drug, Zilretta, seeking removal of confusing limitation of use label, gets FDA approval.

Zacks Equity Research

Has Coherus BioSciences (CHRS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (CHRS) Outperforming Other Medical Stocks This Year?